Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy
Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced…
Read More...
Read More...
